PILA PHARMA AB (SE:PILA)
:PILA
Top Page
PILA PHARMA AB
(PILA)
Select Model
Select Model
Rating:44Neutral
Price Target:
kr1.00
▼(-54.55% Downside)
Action:ReiteratedDate:02/18/26
The score is held down primarily by weak financial performance (large ongoing losses and sustained cash burn) and bearish technicals (below all key moving averages with negative momentum). A clean, debt-free balance sheet and improved equity base provide some stability, while valuation remains hard to support due to negative earnings and no dividend data.
Positive Factors
Clean balance sheet
Zero reported debt and a material equity increase provide structural financial flexibility, lowering insolvency risk and enabling continued R&D investment without immediate refinancing. This durable lower-leverage profile supports runway and strategic optionality over the next several quarters.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow underscores ongoing funding dependence. Continued cash burn will likely require external financing or dilution absent clear inflection in operations, constraining long-term capital allocation and increasing execution risk over the near-to-medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Clean balance sheet
Zero reported debt and a material equity increase provide structural financial flexibility, lowering insolvency risk and enabling continued R&D investment without immediate refinancing. This durable lower-leverage profile supports runway and strategic optionality over the next several quarters.
Read all positive factors
PILA PHARMA AB (PILA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr54.73M
Dividend YieldN/A
Average Volume (3M)235.52K
Price to Earnings (P/E)―
Beta (1Y)0.50
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.37
Shares Outstanding45,682,120
10 Day Avg. Volume194,482
30 Day Avg. Volume235,519
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)4.82
Price to Sales (P/S)63.25
P/FCF Ratio-7.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PILA PHARMA AB Business Overview & Revenue Model
Company Description
PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2a clinical trials for type 2 diabetes. PILA PHARMA AB (publ) was incorporated in 2014...
How the Company Makes Money
null...
PILA PHARMA AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 957.89K | 1.13M | 775.00K | 1.46M | 1.88M | 719.23K |
| Gross Profit | 179.89K | -6.82M | -8.12M | 1.46M | 1.88M | 680.94K |
| EBITDA | -7.04M | -15.57M | -10.11M | -8.81M | -26.76M | -17.16M |
| Net Income | -11.26M | -16.86M | -11.24M | -9.93M | -26.78M | -17.21M |
Balance Sheet | ||||||
| Total Assets | 3.48M | 16.22M | 6.22M | 8.46M | 10.89M | 31.81M |
| Cash, Cash Equivalents and Short-Term Investments | 1.08M | 15.90M | 4.89M | 5.95M | 7.24M | 28.21M |
| Total Debt | 0.00 | 0.00 | 0.00 | 773.08K | 0.00 | 0.00 |
| Total Liabilities | 2.32M | 1.43M | 963.00K | 1.79M | 1.36M | 1.51M |
| Stockholders Equity | 1.16M | 14.78M | 5.26M | 6.66M | 9.53M | 30.30M |
Cash Flow | ||||||
| Free Cash Flow | -8.22M | -9.19M | -7.82M | -4.85M | -9.09M | -9.36M |
| Operating Cash Flow | -8.22M | -9.19M | -7.82M | -4.85M | -9.09M | -9.36M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 6.76M | 20.19M | 6.76M | 3.56M | -11.88M | 35.67M |
PILA PHARMA AB Technical Analysis
Negative
2.20
Price Trends
1.38
Negative
1.80
Negative
2.22
Negative
Market Momentum
-0.05
Negative
46.86
Neutral
42.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PILA, the sentiment is Negative. The current price of 2.2 is above the 20-day moving average (MA) of 1.19, above the 50-day MA of 1.38, and below the 200-day MA of 2.22, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 46.86 is Neutral, neither overbought nor oversold. The STOCH value of 42.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:PILA.
PILA PHARMA AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | kr71.78M | -1.64 | -106.95% | ― | -48.15% | 51.95% | |
44 Neutral | kr54.73M | -4.23 | -601.02% | ― | ― | ― | |
44 Neutral | kr15.23M | -1.19 | -88.65% | ― | 8.46% | 11.73% | |
44 Neutral | kr141.69M | -1.48 | -52.45% | ― | 2.56% | 52.76% | |
42 Neutral | kr87.82M | -1.86 | -120.13% | ― | ― | 49.09% | |
41 Neutral | kr3.64M | -3.06 | -213.85% | ― | ― | ― |
* Healthcare Sector Average
SE:PILA
PILA PHARMA AB
1.20
-1.58
-56.81%
SE:BIOSGN
Biosergen AB
37.40
3.00
8.72%
SE:LPGO
Lipigon Pharmaceuticals AB
0.01
-0.22
-95.20%
SE:EXPRS2
ExpreS2ion Biotech Holding AB
4.32
-17.08
-79.84%
SE:NXTCL
NextCell Pharma AB
1.27
-1.59
-55.52%
SE:SPAGO
Spago Nanomedical AB
0.11
-0.05
-31.65%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.